KDNY · Chinook Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | $6.13M | $51.63M | $827.0K | $17.26M | $50.68M | $17.24M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $141.21M | $96.99M | $36.05M | $67.05M | $75.84M | $89.38M |
| SG&A | $36.29M | $31.90M | $19.07M | $34.80M | $36.03M | $33.75M |
| Total Operating Expenses | - | - | $57.05M | $107.40M | $116.45M | $123.69M |
| D&A | $3.40M | $3.10M | $1.10M | $4.30M | $4.37M | $3.43M |
| Operating Income | ($185.08M) | ($99.04M) | ($56.23M) | ($90.14M) | ($101.36M) | ($106.45M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $4.34M | $2.09M | ($2.00M) | ($2.41M) | ($783.0K) | ($11.36M) |
| Net Income | ($187.87M) | ($102.94M) | ($81.62M) | ($82.37M) | ($95.36M) | ($91.86M) |
| EPS - Basic | ($6.20) | - | - | - | - | - |
| EPS - Diluted | ($6.20) | - | - | - | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $115.44M | $181.72M | $187.75M | $59.62M | $126.31M | $157.61M |
| Accounts Receivable | - | - | $262.0K | $342.0K | $12.04M | $989.0K |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $9.75M | $8.58M | $4.00M | $414.0K | $1.46M | $1.15M |
| Current Assets | $385.59M | $300.64M | $254.08M | $217.90M | $282.98M | $350.13M |
| Total Assets | $574.08M | $563.80M | $429.00M | $291.31M | $357.50M | $445.13M |
| Current Liabilities | $50.84M | $40.09M | $22.81M | $21.60M | $30.52M | $41.40M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $132.14M | $110.16M | $94.38M | $225.72M | $222.19M | $207.66M |
| Stockholders' Equity | $441.94M | $453.64M | $334.62M | $65.59M | $135.31M | $237.47M |
| Retained Earnings | ($419.63M) | ($231.77M) | ($128.83M) | ($486.90M) | ($404.53M) | ($283.86M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($117.48M) | ($102.74M) | ($55.85M) | ($65.51M) | ($86.08M) | ($88.86M) |
| Investing Cash Flow | ($99.99M) | ($112.64M) | $109.67M | ($1.76M) | ($32.06M) | $88.94M |
| Financing Cash Flow | $151.43M | $209.52M | $124.29M | $743.0K | $43.09M | $82.05M |
| CapEx | $1.65M | $1.88M | $797.0K | $1.26M | $2.37M | $5.15M |
| Free Cash Flow | ($119.13M) | ($104.62M) | ($56.65M) | ($66.77M) | ($88.44M) | ($94.01M) |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -3020.3% | -191.8% | -6798.9% | -522.3% | -200.0% | -617.5% |
| EBITDA margin | -2964.8% | -185.8% | -6665.9% | -497.4% | -191.4% | -597.6% |
| Net margin | -3065.7% | -199.4% | -9869.6% | -477.3% | -188.2% | -532.9% |
| Free cash flow margin | -1944.1% | -202.7% | -6849.5% | -386.9% | -174.5% | -545.3% |
| FCF / Net income | 0.63 | 1.02 | 0.69 | 0.81 | 0.93 | 1.02 |
| R&D / Revenue | 2304.4% | 187.9% | 4359.3% | 388.5% | 149.6% | 518.5% |
| SG&A / Revenue | 592.2% | 61.8% | 2306.0% | 201.6% | 71.1% | 195.8% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -32.7% | -18.3% | -19.0% | -28.3% | -26.7% | -20.6% |
| Return on equity | -42.5% | -22.7% | -24.4% | -125.6% | -70.5% | -38.7% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 7.59 | 7.50 | 11.14 | 10.09 | 9.27 | 8.46 |
| Quick ratio | 7.59 | 7.50 | 11.14 | 10.09 | 9.27 | 8.46 |
| Cash ratio | 2.27 | 4.53 | 8.23 | 2.76 | 4.14 | 3.81 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.30 | 1.24 | 1.28 | 4.44 | 2.64 | 1.87 |
| Liabilities / Assets | 0.23 | 0.20 | 0.22 | 0.77 | 0.62 | 0.47 |
| Efficiency | ||||||
| Asset turnover | 0.01 | 0.09 | 0.00 | 0.06 | 0.14 | 0.04 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | 116d | 7d | 87d | 21d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -88.1% | 6142.4% | -95.2% | -65.9% | 194.0% | -66.0% |
| Revenue CAGR (3y) | -29.2% | 0.6% | -63.7% | -30.2% | 294.1% | - |
| Revenue CAGR (5y) | -18.7% | 0.4% | -0.0% | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -86.9% | -76.1% | 37.6% | 11.1% | 4.8% | -48.1% |
| Net income growth (YoY) | -82.5% | -26.1% | 0.9% | 13.6% | -3.8% | -0.8% |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -13.9% | -84.7% | 15.2% | 24.5% | 5.9% | 14.5% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -2.6% | 35.6% | 410.1% | -51.5% | -43.0% | 4.5% |
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
0.21
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- -No share dilution
- -Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing CHINOOK THERAPEUTICS against the 5 most active filers in the same SIC group.